RedHill Biopharma Announced Results From New In Vivo Studies Of Opaganib For Gastrointestinal Acute Radiation Syndrome, Undertaken As Part Of The U.S. Government's Radiation And Nuclear Countermeasures Program Contract That Further Confirms Opaganib's...

Redhill Biopharma宣佈了新的人體內研究結果，研究Opaganib用於急性放射性腸道綜合症，這是美國政府的放射性和核對策計劃合同的一部分，進一步確認了Opaganib的...

Benzinga · 12/10 20:14

RedHill Biopharma Announced Results From New In Vivo Studies Of Opaganib For Gastrointestinal Acute Radiation Syndrome, Undertaken As Part Of The U.S. Government's Radiation And Nuclear Countermeasures Program Contract That Further Confirms Opaganib's Protective Activity In Animal Models

Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radiological incident
There are currently no known approved therapies for gastrointestinal acute radiation syndrome (GI-ARS)
Positive results from new in vivo studies of opaganib as a treatment for GI-ARS, undertaken as part of the U.S. government's Radiation and Nuclear Countermeasures Program (RNCP) product pipeline development contract, further confirm opaganib's protective activity
Discussions now ongoing with the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID), which leads the RNCP, regarding plans for the next phase of development along the U.S. Food and Drug Administration's (FDA) Animal Rule pathway to approval

日益緊張的地緣政治局勢和國內安全關切看漲呼籲開發可能的治療方案，以便在發生大規模傷亡的核或放射性事件時能夠迅速和輕鬆動員。
目前尚未有已知的批准治療胃腸道急性輻射綜合症（GI-ARS）的療法。
關於作爲治療 GI-ARS 的 Opaganib 的新體內研究的積極結果，這是美國政府的輻射和核對策計劃（RNCP）產品管道開發合同的一部分，進一步確認了 Opaganib 的保護活性。
目前與國立衛生研究院（NIH）的國家過敏和傳染病研究所（NIAID）進行的討論，NIAID 負責 RNCP，關於沿着美國食品和藥物管理局（FDA）的動物規則途徑進行審批的下一階段發展計劃。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。